Kollidon VA64 Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Area of Science:

• Neuroscience
• Traumatic Brain Injury Research
• Pharmacology

Background:

• Traumatic brain injury (TBI) can lead to cell death due to loss of plasmalemmal integrity.
• Previous studies showed promise for the membrane resealing agent Kollidon VA64 (VA64) in a controlled cortical impact (CCI) model of TBI.

Purpose of the Study:

• To evaluate the efficacy of Kollidon VA64 as a potential therapeutic agent for TBI across three distinct pre-clinical rat models.
• To assess the impact of low and high doses of VA64 on behavioral, histopathological, and serum biomarker outcomes following TBI.

Main Methods:

• Rats were subjected to three TBI models: fluid percussion injury (FPI), CCI, and penetrating ballistic-like brain injury (PBBI).
• Animals were randomized to sham, TBI+vehicle, TBI+low-dose VA64 (0.4 g/kg), or TBI+high-dose VA64 (0.8 g/kg) groups.
• A single intravenous VA64 bolus was administered 15 minutes post-injury, with outcomes assessed over 21 days.

Main Results:

• Low-dose VA64 showed no significant benefit in FPI or PBBI models, but provided intermediate improvements in beam balance and Morris water maze in the CCI model.
• High-dose VA64 worsened motor performance in FPI and showed no benefit in CCI or PBBI models.
• Biomarker analysis revealed increased GFAP in TBI groups, with a modest benefit from low-dose VA64 in FPI at 24 hours. UCH-L1 levels increased at 4 hours post-TBI but were not affected by treatment.

Conclusions:

• Kollidon VA64 demonstrated modest and inconsistent therapeutic effects across different TBI models and doses.
• The limited and variable efficacy observed suggests that further investigation into VA64 for TBI treatment may not be warranted.
• The study highlights the complexity of TBI treatment and the need for model-specific evaluations of potential therapies.